Single-institution clinical experience using robust intensity modulated proton therapy in chordoma and chondrosarcoma of the mobile spine and sacrum: Feasibility and need for plan adaptation

• Published in: Radiotherapy and oncology 2022-01, Vol.166, p.58-64
• Main Authors: Kroesen, Michiel, Miladinovic, Vesna, Hutschemaekers, Stefan A.J., Jacobs, Jenneke, van der Vos, Charlotte, Wolf, Anne Lisa, Hoogeman, Mischa S., van Vulpen, Marco, Bloem, Johan L., P.D.S. Dijkstra, Sander, Peul, Wilco C., Penninkhof, Joan J., Krol, Augustinus D.G.
• Format: Article
• Language: English
• Subjects: Chondrosarcoma; Chordoma; Intensity modulated proton therapy; Pencil beam scanning; Robust planning
• ISSN: 0167-8140; 1879-0887
• DOI: 10.1016/j.radonc.2021.11.020

•Robust planning is feasible in proton beam therapy of chordoma and chondrosarcoma patients.•Despite robust planning, plan adaptations are still required in case of anatomical changes.•Monitoring of anatomical changes is warranted. Due to its specific physical characteristics, proton irradiation is especially suited for irradiation of chordomas and chondrosarcoma in the axial skeleton. Robust plan optimization renders the proton beam therapy more predictable upon individual setup errors. Reported experience with the planning and delivery of robustly optimized plans in chordoma and chondrosarcoma of the mobile spine and sacrum, is limited. In this study, we report on the clinical use of robustly optimized, intensity modulated proton beam therapy in these patients. We retrospectively reviewed patient, treatment and acute toxicity data of all patients with chordoma and chondrosarcoma of the mobile spine and sacrum, treated between 1 April 2019 and 1 April 2020 at our institute. Anatomy changes during treatment were evaluated by weekly cone-beam CTs (CBCT), supplemented by scheduled control-CTs or ad-hoc control-CTs. Acute toxicity was scored weekly during treatment and at 3 months after therapy according to CTCAE 4.0. 17 chordoma and 3 chondrosarcoma patients were included. Coverage of the high dose clinical target volume was 99.8% (range 56.1–100%) in the nominal and 80.9% (range 14.3–99.6%) in the voxel-wise minimum dose distribution. Treatment plan adaptation was needed in 5 out of 22 (22.7%) plans. Reasons for plan adaptation were either reduced tumor coverage or increased dose to the OAR. Robustly optimized intensity modulated proton beam therapy for chordoma and chondrosarcoma of the mobile spine is feasible. Plan adaptations due to anatomical changes were required in approximately 23 percent of treatment courses.